Q3 EPS Estimate for Protalix BioTherapeutics Cut by Analyst

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2025 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a note issued to investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their prior forecast of $0.07. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q4 2025 earnings at $0.05 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.35 EPS.

Separately, Wall Street Zen downgraded shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $15.00.

Protalix BioTherapeutics Stock Up 5.1%

NYSE PLX traded up $0.08 during trading hours on Tuesday, hitting $1.66. The company had a trading volume of 690,192 shares, compared to its average volume of 835,539. The firm has a market cap of $132.36 million, a P/E ratio of -12.77 and a beta of -0.21. Protalix BioTherapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $3.10. The business has a fifty day simple moving average of $1.49 and a 200-day simple moving average of $2.01.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several hedge funds have recently made changes to their positions in the company. Evergreen Capital Management LLC purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $254,000. Bank of America Corp DE grew its position in Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company's stock worth $32,000 after purchasing an additional 21,886 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $56,000. Diametric Capital LP purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $212,000. Finally, Invesco Ltd. purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $67,000. Hedge funds and other institutional investors own 16.53% of the company's stock.

Insider Buying and Selling at Protalix BioTherapeutics

In related news, Director Aharon Schwartz acquired 129,000 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was bought at an average price of $1.60 per share, for a total transaction of $206,400.00. Following the transaction, the director owned 303,000 shares of the company's stock, valued at approximately $484,800. The trade was a 74.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.50% of the stock is currently owned by company insiders.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.